Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IGN-AMP001 in Hidradenitis Suppurativa
NCT04541550Phase 1Withdrawn
- Sponsor
- IntegoGen
- Start
- Apr 2021
- Primary completion
- Jul 2021
- Modality
- Small Molecules, Tissue Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of AMP-001 in hidradenitis suppurativa (HS) (3 arms), sponsored by IntegoGen. Primary endpoint: Total number of Adverse Events at 6 months. Planned start Apr 2021; status: withdrawn.
02
Drugs
AMP-001
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on NCT04541550.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04541550.